Trial Profile
A 24-month open label, extension phase, single-centre trial to evaluate the Imatinib mesylate in the treatment of diffuse cutaneous systemic sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- 08 Dec 2015 New trial record